Mutual of America Capital Management LLC lessened its holdings in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 4.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 8,241 shares of the company’s stock after selling 390 shares during the quarter. Mutual of America Capital Management LLC’s holdings in DaVita were worth $932,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in DVA. Brown Advisory Inc. lifted its position in shares of DaVita by 1.5% during the 4th quarter. Brown Advisory Inc. now owns 22,967 shares of the company’s stock worth $2,613,000 after purchasing an additional 338 shares during the last quarter. State of Michigan Retirement System lifted its position in shares of DaVita by 2.8% during the 4th quarter. State of Michigan Retirement System now owns 18,000 shares of the company’s stock worth $2,048,000 after purchasing an additional 490 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of DaVita during the 4th quarter worth about $1,398,000. Commonwealth Equity Services LLC lifted its position in shares of DaVita by 42.3% during the 4th quarter. Commonwealth Equity Services LLC now owns 32,121 shares of the company’s stock worth $3,654,000 after purchasing an additional 9,555 shares during the last quarter. Finally, Illinois Municipal Retirement Fund lifted its position in shares of DaVita by 23.2% during the 4th quarter. Illinois Municipal Retirement Fund now owns 19,065 shares of the company’s stock worth $2,169,000 after purchasing an additional 3,588 shares during the last quarter. Institutional investors and hedge funds own 87.47% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on DVA. Bank of America cut their price objective on DaVita from $110.00 to $90.00 and set an “underperform” rating for the company in a research report on Tuesday, June 21st. Truist Financial lowered their price target on DaVita from $110.00 to $90.00 and set a “hold” rating on the stock in a research note on Wednesday, June 22nd. Finally, StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $122.00.
DaVita Trading Up 0.9 %
DVA stock opened at $84.16 on Friday. DaVita Inc. has a 1-year low of $74.97 and a 1-year high of $136.48. The firm has a market cap of $7.96 billion, a P/E ratio of 10.02, a P/E/G ratio of 1.04 and a beta of 1.19. The business’s 50 day moving average is $87.53 and its 200-day moving average is $103.24. The company has a current ratio of 1.29, a quick ratio of 1.25 and a debt-to-equity ratio of 8.53.
DaVita (NYSE:DVA – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.24). DaVita had a net margin of 7.78% and a return on equity of 78.24%. The company had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.89 billion. During the same quarter in the prior year, the company posted $2.09 earnings per share. The company’s revenue for the quarter was down .1% on a year-over-year basis. Equities analysts anticipate that DaVita Inc. will post 7.8 earnings per share for the current fiscal year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- Procter’s Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.